tecovirimat
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Smallpox
Conditions
Smallpox
Trial Timeline
Jun 19, 2015 → Aug 24, 2016
NCT ID
NCT02474589About tecovirimat
tecovirimat is a phase 3 stage product being developed by SIGA Technologies for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT02474589. Target conditions include Smallpox.
What happened to similar drugs?
3 of 7 similar drugs in Smallpox were approved
Approved (3) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02474589 | Phase 3 | Completed |
Competing Products
20 competing products in Smallpox
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1769 | Moderna | Phase 2 | 0 |
| Smallpox vaccine, LISTER strain, from chick embryo cells | Sanofi | Phase 2 | 35 |
| MVA (smallpox vaccine) | Sanofi | Phase 1 | 21 |
| ACAM3000 MVA Vaccine | Sanofi | Phase 1 | 29 |
| MVA Smallpox vaccine + Placebo | Sanofi | Phase 2 | 35 |
| ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: Dryvax | Sanofi | Phase 2 | 27 |
| IMVAMUNE (MVA-BN) | Bavarian Nordic | Phase 2 | 32 |
| MVA-BN | Bavarian Nordic | Phase 1 | 26 |
| IMVAMUNE® | Bavarian Nordic | Phase 2 | 32 |
| LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE® | Bavarian Nordic | Phase 2 | 32 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 32 |
| FD MVA-BN | Bavarian Nordic | Phase 3 | 37 |
| IMVAMUNE® | Bavarian Nordic | Phase 3 | 37 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 32 |
| MVA-BN® (IMVAMUNE) + Placebo | Bavarian Nordic | Phase 2 | 32 |
| Elstree-BN | Bavarian Nordic | Phase 1 | 26 |
| ACAM2000 | Emergent BioSolutions | Phase 3 | 30 |
| VIGIV | Emergent BioSolutions | Pre-clinical | 23 |
| ACAM2000® smallpox vaccine | Emergent BioSolutions | Pre-clinical | 16 |
| Brincidofovir | Emergent BioSolutions | Phase 1 | 19 |